These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7374441)

  • 1. Mechanism of the hypolipemic effect of clofibrate in glucose-fed men.
    Wolfe BM; Ahuja SP; Marliss EB
    Metabolism; 1980 Mar; 29(3):279-88. PubMed ID: 7374441
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
    Wolfe BM; Kane JP; Havel RJ; Brewster HP
    J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
    Naruszewicz M; Szostak WB; Cybulska C; Kozłowska M; Chotkowska E
    Atherosclerosis; 1980 Apr; 35(4):383-92. PubMed ID: 7378119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free fatty acid and carbohydrate metabolism of the working forearm muscle in type IV hyperlipoproteinaemia.
    Olsson AG; Eklund B; Riccardi G; Walldius G; Kaijser L
    Eur J Clin Invest; 1977 Dec; 7(6):549-56. PubMed ID: 204495
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 7. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of phenformin on fat and lactate metabolism and insulin production in starved normal subjects.
    Lyngsoe J; Bitsch V; Trap-Jensen J
    Metabolism; 1972 Mar; 21(3):179-86. PubMed ID: 5060759
    [No Abstract]   [Full Text] [Related]  

  • 14. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic production of VLDL-triglycerides. Dependence of portal substrate and insulin concentration.
    Vogelberg KH; Gries FA; Moschinski D
    Horm Metab Res; 1980 Dec; 12(12):688-94. PubMed ID: 7009368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial lipid and carbohydrate metabolism in fasting men during prolonged exercise.
    Kaijser L; Lassers BW; Wahlqvist ML; Carlson LA
    J Appl Physiol; 1972 Jun; 32(6):847-58. PubMed ID: 5034348
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
    Larsen ML; Illingworth DR; O'Malley JP
    Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR; Yeshurun D; Jackson RL; Gotto AM
    Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
    [No Abstract]   [Full Text] [Related]  

  • 20. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.